- Home
- VYGR vs UHG Comparison
VYGR vs UHG Comparison
Compare VYGR & UHG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYGR
- UHG
- Stock Information
- Founded
- VYGR 2013
- UHG 2004
- Country
- VYGR United States
- UHG United States
- Employees
- VYGR N/A
- UHG N/A
- Industry
- VYGR Biotechnology: Pharmaceutical Preparations
- UHG Homebuilding
- Sector
- VYGR Health Care
- UHG Consumer Discretionary
- Exchange
- VYGR Nasdaq
- UHG Nasdaq
- Market Cap
- VYGR 156.0M
- UHG 152.4M
- IPO Year
- VYGR 2015
- UHG N/A
- Fundamental
- Price
- VYGR $2.97
- UHG $3.31
- Analyst Decision
- VYGR Strong Buy
- UHG
- Analyst Count
- VYGR 8
- UHG 0
- Target Price
- VYGR $14.33
- UHG N/A
- AVG Volume (30 Days)
- VYGR 841.7K
- UHG 334.6K
- Earning Date
- VYGR 08-05-2025
- UHG 08-07-2025
- Dividend Yield
- VYGR N/A
- UHG N/A
- EPS Growth
- VYGR N/A
- UHG N/A
- EPS
- VYGR N/A
- UHG 0.76
- Revenue
- VYGR $66,958,000.00
- UHG $449,877,017.00
- Revenue This Year
- VYGR N/A
- UHG N/A
- Revenue Next Year
- VYGR $78.88
- UHG N/A
- P/E Ratio
- VYGR N/A
- UHG $4.40
- Revenue Growth
- VYGR N/A
- UHG 5.24
- 52 Week Low
- VYGR $2.65
- UHG $1.60
- 52 Week High
- VYGR $9.55
- UHG $6.93
- Technical
- Relative Strength Index (RSI)
- VYGR 41.86
- UHG 56.38
- Support Level
- VYGR $3.24
- UHG $3.10
- Resistance Level
- VYGR $3.64
- UHG $3.70
- Average True Range (ATR)
- VYGR 0.27
- UHG 0.41
- MACD
- VYGR -0.02
- UHG -0.04
- Stochastic Oscillator
- VYGR 6.17
- UHG 19.54
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
About UHG United Homes Group Inc
United Homes Group Inc operates as a homebuilder which operates with a land-light idea in the Southeast. The company currently has a presence in South Carolina, North Carolina, and Georgia and focuses on providing high-quality, affordable homes for the entry-level and first-move-up segments. The company has three reportable segments: GSH South Carolina, Rosewood, and Other.